



PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: '**ASRU_establishment name_PPL number_PPLh surname_date_sc18**' and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number]

Establishment Licence name	University of Cambridge
Establishment Licence number	80/2802 X81BD37B1
Name of PPL holder	Ziad Mallat
PPL number	PP9485757
Protocol no	4
Protocol title	Breeding and maintenance of genetically altered animals
Severity classification	Mild

1. Date of incident	30/06/2025
2. Species	Mice
3. Brief details of study and how the limits or constraints have been breached	Exceeded the maximum number of animals allowed on the protocol
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	Yes, an NTCO has suggested to write an SC18 report mentioning the exceeded number of mice used for the protocol
5. Cause of Problem, if known	At the outset, we estimated that a maximum of 25,000 mice would be used under this protocol over the five-year duration of the project licence. We have now reached this number, approximately one year before the licence's scheduled end date (06 July 2026). There are several contributing factors to this earlier-than-expected usage. Firstly, Dr. Xuan Li, who was part of my research group, was initially expected to obtain her own project licence in 2022. However, she was only able to secure it last year, resulting in continued use of my PPL for her experiments during that interim period. Secondly, extensive revisions requested by external reviewers for multiple manuscripts necessitated a significant number of additional experiments, thereby increasing mouse usage. While these experiments were not originally planned, they ultimately contributed to several high-impact publications, including papers in Nature, Immunity, and Nature Cardiovascular Research. In response, we have recently implemented measures to substantially reduce mouse usage under the current licence, including the cessation or downsizing of several breeding colonies
6. Action that has been or will be taken <i>(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)</i>	In addition to SC18, a lay summary has also been submitted by Ziad Mallat. Licence is being amended to request an increase of the number of mice that will be used in protocol 4. At present, there are 881 mice under Protocol 4. Assuming 3 to 4 breeding periods, we estimate that approximately 4,000 additional mice will be required under Protocol 4 until the expiry date of the PPL on 06 July 2026.

7. Reported by (name)	Judhell Manansala
8. Date	08/07/2025

*****For official use*****

Inspector's comments and recommendations:

Comments and recommendations	
Inspector name	
Date	